Phillip L. Campbell

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos et al. · The Lancet Oncology · 2020 · 587 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

The carbonic anhydrase domain of receptor tyrosine phosphatase β is a functional ligand for the axonal cell recognition molecule contactin

Elior Peles, Moshe Nativ, Phillip L. Campbell et al. · Cell · 1995 · 395 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Paolo Ghia, Andrzej Pluta, Daniel Lysák et al. · Journal of Clinical Oncology · 2020 · 362 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

IL-1β AND TNF-α IN PROSTATIC SECRETIONS ARE INDICATORS IN THE EVALUATION OF MEN WITH CHRONIC PROSTATITIS

Robert B. Nadler, Alisa E. Koch, Elizabeth A. Calhoun et al. · The Journal of Urology · 2000 · 214 citations

Medicine, Immunology, Urology +17

Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production

Salahuddin Ahmed, Hubert Marotte, K.H. Kwan et al. · Proceedings of the National Academy of Sciences · 2008 · 146 citations · Full text

Medicine, Immunology, Pharmacology +17